Pliant Therapeutics (PLRX) Common Equity (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Common Equity data on file, last reported at $165.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at $165.2 million, down 35.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $165.2 million (down 35.77% YoY), and the FY2025 annual result was $181.2 million, down 40.41% from the prior year.
• Common Equity fell to $165.2 million in Q1 2026 per PLRX's latest filing, from $181.2 million in the prior quarter.
• Over five years, Common Equity peaked at $561.9 million in Q1 2023 and troughed at $147.8 million in Q2 2022.
• A 5-year average of $326.3 million and a median of $313.3 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity soared 260.7% in 2023, then plunged 43.95% in 2025.
• A 5-year view of Common Equity shows it stood at $313.3 million in 2022, then surged by 51.14% to $473.6 million in 2023, then sank by 35.79% to $304.1 million in 2024, then tumbled by 40.41% to $181.2 million in 2025, then slipped by 8.85% to $165.2 million in 2026.
• Business Quant data shows PLRX's Common Equity at $165.2 million in Q1 2026, $181.2 million in Q4 2025, and $200.3 million in Q3 2025.